CFRX:NSD-ContraFect Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.34

Change

+0.06 (+1.14)%

Market Cap

USD 0.15B

Volume

0.12M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. ContraFect Corporation has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. The company also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.05 (-0.44%)

USD62.06B 23.39 18.26
REGN Regeneron Pharmaceuticals, Inc

+2.30 (+0.43%)

USD57.14B 19.62 14.64
MRNA Moderna, Inc

-1.96 (-1.47%)

USD52.62B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.87 (+1.18%)

USD34.53B 36.64 33.83
SGEN Seagen Inc

-3.03 (-1.63%)

USD33.25B 70.16 70.76
BGNE BeiGene, Ltd

+17.51 (+4.90%)

USD32.53B N/A N/A
RPRX Royalty Pharma plc

+0.74 (+1.47%)

USD31.52B 22.60 11.90
GMAB Genmab A/S

-0.01 (-0.02%)

USD28.49B 26.59 3.08
BNTX BioNTech SE

+3.01 (+2.85%)

USD25.39B -99,999.99 N/A
INCY Incyte Corporation

+3.99 (+4.25%)

USD20.56B 47.64 35.20

ETFs Containing CFRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.74% 31% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.74% 31% F 46% F
Trailing 12 Months  
Capital Gain 385.45% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 385.45% 96% A 96% A
Trailing 5 Years  
Capital Gain 46.30% 63% D 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.30% 63% D 46% F
Average Annual (5 Year Horizon)  
Capital Gain 301.06% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 301.06% 97% A+ 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 607.02% 3% F 2% F
Risk Adjusted Return 49.60% 77% C+ 71% C-
Market Capitalization 0.15B 27% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.80 36% F 52% F
Price/Book Ratio 8.21 29% F 20% F
Price / Cash Flow Ratio -5.35 38% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -283.93% 8% F 2% F
Return on Invested Capital -264.30% 6% F 3% F
Return on Assets -48.44% 18% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.55 18% F 11% F
Short Percent 7.85% 42% F 28% F
Beta 1.08 72% C- 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.